Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evolent HealthEVH -9.05%63 Debt-to-EBITDA is 19.40 as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 63/100 and a GF Value™ of $11.43 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Evolent Health ranks worse than 209643.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Evolent Health's Debt-to-EBITDA or its related term are showing as below:
EVH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -53.24 Med: -1.47 Max: 23.01
Current: -3.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Evolent Health was 23.01. The lowest was -53.24. And the median was -1.47.
EVH's Debt-to-EBITDA is ranked worse than 100% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs EVH: -3.09
Evolent Health (NYSE:EVH) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Evolent Health Debt-to-EBITDA Related Terms
Evolent Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Evolent Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Evolent Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evolent Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Evolent Health (EVH) has a Debt-to-EBITDA of 19.40 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolent Health. According to the industry distribution chart, Evolent Health ranks #999999 out of 477 companies in the Healthcare Providers & Services industry.
Is Evolent Health's Debt-to-EBITDA too high?
Evolent Health's current Debt-to-EBITDA is 19.40. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Evolent Health's value of 19.40 is 773.9% above this industry median. Based on the distribution chart, Evolent Health ranks #999999 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Debt-to-EBITDA compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #999999 out of 477 companies for Debt-to-EBITDA. This places Evolent Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. Evolent Health's value of 19.40 is 773.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolent Health's current Debt-to-EBITDA of 19.40 is 773.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolent Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current Debt-to-EBITDA is 19.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.43, compared to a current price of $4.22 — trading 63.1% below its estimated fair value. The current Debt-to-EBITDA is 19.40 and 773.9% above the Healthcare Providers & Services industry median of 2.22. Evolent Health's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Evolent Health (EVH), the current Debt-to-EBITDA is 19.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $4.22 is trading 63.1% below its estimated GF Value™ of $11.43.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
Debt-to-EBITDA: 19.40
GF Value™: $11.43 vs. price of $4.22 (63.1% below fair value)
Industry Position: 773.9% above the Healthcare Providers & Services median (#999999 of 477)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
63GF Score
Get the complete analysis for EVH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
